Stem Cell Therapy for Hip Osteoarthritis

What This Article Covers

Stem cell injections for hip osteoarthritis (OA) — using a patient's own bone marrow or fat, or donor-derived cells — are being explored as a possible earlier stop on the road to hip replacement. This article lays out what the clinical evidence actually shows, where it falls short, and why no such product is FDA-approved for this use, so you can weigh the encouraging early signals against the real gaps in the research.

How It's Thought to Work

Hip osteoarthritis develops as cartilage cushioning the ball-and-socket joint wears down, causing bone-on-bone friction, inflammation, and pain. Mesenchymal stem cells (MSCs) — usually harvested from a patient's own bone marrow (bone marrow concentrate) or fat (adipose-derived, including stromal vascular fraction), sometimes from a donor — are injected into the joint to calm inflammation and, in theory, support the joint environment.

Worth being precise here: MSCs are not believed to regrow hip cartilage the way a graft would. The leading theory is that they act through paracrine signaling — releasing anti-inflammatory, growth-supportive molecules that may ease pain and improve function, rather than rebuilding lost tissue. Protocols vary widely in cell dose, processing method, and source, and that variation is one reason findings below are mixed.

What the Evidence Shows

Hip osteoarthritis has far less high-quality research behind it than knee OA — most large randomized trials for MSC injections have focused on the knee. Still, the hip-specific data that exists is genuinely encouraging in places.

A 2024 systematic review in the European Journal of Orthopaedic Surgery & Traumatology pooled 10 studies covering 316 patients treated with bone marrow, adipose, or stromal-vascular-fraction injections for hip OA. Its largest study — 147 patients — reported that 73% saw improvement in pain (VAS) scores, with 63% improving by more than 20 points. Adverse events across the pooled studies were minimal: one donor-site hematoma and one case of transient joint pain, both resolving on their own, with no serious complications — a genuinely good result for a condition that otherwise trends toward surgery.

A smaller 2025 Cureus scoping review of 9 hip OA studies (6 to 96 patients each) found average pain-scale reductions of roughly 30–50%, and one early cohort study documented Harris Hip Scores climbing from 61.9 to 85.7 and VAS pain scores dropping from 4.2 to 1.1 after bone-marrow-derived MSC injections (Journal of Hip Preservation Surgery, 2017) — a meaningful jump on a scale where higher means better function.

Now the caveats, which matter just as much. Almost none of these hip studies had a placebo control group — only one did, per the 2024 review — making it hard to separate a true treatment effect from the placebo response well documented in joint injections generally. Follow-up rarely extends past 1–3 years, and imaging hasn't shown consistent cartilage regrowth despite reported symptom relief. In the Cureus review, 17 of 55 patients in one study still went on to total hip replacement, averaging about 495 days after injection — for many, this appears to delay rather than replace surgery. A related meta-analysis of 18 placebo-controlled knee OA trials (1,174 patients, Frontiers in Endocrinology, 2024) did find statistically significant pain and function improvement over placebo at 6 and 12 months — useful context, though it doesn't prove the same effect size in the hip.

Regulatory reality: per the FDA's consumer alert, “none of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.” The FDA has warned that some clinics market unproven products carrying real safety risks.

Who Might Be a Candidate

• Adults with mild-to-moderate hip OA who haven't found relief with physical therapy, weight management, or NSAIDs, and want options short of hip replacement.
• Patients enrolling through a registered clinical trial (searchable on ClinicalTrials.gov) or working with a physician transparent about the unapproved status, cost, and evidence gaps.
• People without contraindications like active infection or joint damage too advanced (bone-on-bone collapse) to plausibly benefit.
• Anyone who expects, at best, temporary pain relief and functional gains — not cartilage regeneration or a substitute for eventual surgery.

Bottom Line

The hip-specific evidence is more encouraging than dismissive coverage sometimes suggests — several small-to-midsize studies report meaningful drops in pain and gains in function, with a low rate of serious side effects. But this remains investigational medicine: sample sizes are modest, placebo-controlled hip trials are nearly nonexistent, imaging hasn't confirmed cartilage repair, and a meaningful share of treated patients still progress to hip replacement within a couple of years. No stem cell product is FDA-approved for hip osteoarthritis in the US. Treat this as an unproven, out-of-pocket intervention best pursued through a registered clinical trial or with an orthopedic specialist candid about what the data does and doesn't show.